# US 2020/0390760 A1 · Purine inhibitors of human phosphatidylinositol 3-kinase delta

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390760 A1
- Document ID: US20200390760A1
- Status: Published application
- Kind: A1
- Application number: 16/764,107
- Filed: 2018-12-12
- Published: 2020-12-17
- Earliest claimed: 2017-12-18
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Meredeth A. McGowan; Jason D. Katz; Hua Zhou; David James Witter; Chaomin Li; Kathryn A. Lipford; Joey L. Methot; Abdelghani A. Achab; Xavier Fradera; Shimin Xu; Jianmin Fu
- Web page: https://patentgrep.com/patent/US20200390760A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K 31/537: spiro-condensed or forming part of bridged ring systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 471/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 498/10: Spiro-condensed systems
- C07D 513/10: Spiro-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein
A is selected from:
wherein A is substituted with 0, 1, 2, or 3 R4, each R4 is independently selected from C1-C10 alkyl, C1-10 haloalkyl, C3-12 heterocycloalkylC0-6 alkyl, C3-12 cycloalkyl(C0-6 alkyl), amino, C3-12 cycloalkyl(C0-6 alkyl)aminocarbonyl, C1-6 alkylamino(C0-6 alkyl), C3-12 heterocycloalkylcarbonyl(C0-6 alkyl), C1-10 alkylcarbonyl(C0-6 alkyl), C3-12 cycloalkylcarbonyl(C0-6 alkyl), C1-10 alkylcarboxy, or C1-10 alkyloxy(C0-6 alkyl), wherein each R4 is independently substituted by 0, 1, 2, or 3 R5 independently selected from halogen, hydroxy, C1-6 alkyl, C1-4 alkoxy, or C1-6 haloalkyl;
each R1 and R2 is independently selected from: hydrogen, or cyano provided that only one of R1 or R2 is cyano and the other is hydrogen; and
R3 is hydrogen, C1-6 haloalkyl, or C1-6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A is selected from
and wherein A is substituted with 0, 1, 2, or 3 R4.

### Claim 3 (depends on 2)

The compound of claim 2, wherein A is selected from
and wherein A is substituted with 0, 1, 2, or 3 R4.

### Claim 4 (depends on 1)

The compound of claim 1, wherein each R4 is independently selected from C1-C10 alkyl, C1-10 haloalkyl, C3-12 heterocycloalkylC0-6 alkyl having 1, 2 or 3 heteroatoms selected from nitrogen or oxygen, C3-12 cycloalkyl(C0-6 alkyl), amino, C3-12 cycloalkyl(C0-6 alkyl)aminocarbonyl, C1-6 alkylamino(C0-6 alkyl), C3-12 heterocycloalkylcarbonyl(C0-6 alkyl) having 1, 2 or 3 heteroatoms selected from nitrogen or oxygen, C1-10 alkylcarbonyl(C0-6 alkyl), C3-12 cycloalkylcarbonyl(C0-6 alkyl), C1-10 alkylcarboxy, or C1-10 alkyloxy(C0-6 alkyl), wherein each R4 is independently substituted by 0, 1, 2, or 3 R5.

### Claim 5 (depends on 4)

The compound of claim 4, wherein each R4 is independently selected from cyclopropylmethyl, cyclobutylmethyl, 2,2,2-trifluoroethyl, propyl, oxetanylmethyl, 2,2,2-trifluoro-1-methylethyl, methylaminoethyl, methoxyethyl, cyclopropylaminocarbonyl, ethylcarbonyl, ethyl, isobutyl, methyl, morpholinyl, cyclopropylcarbonyl, cyclobutylcarbonyl, piperidinyl, pyrrolidinylcarbonyl, 2-oxa-6-azaspiro[3.3]heptylcarbonyl, (cyclopropylmethyl)aminocarbonyl, azetidinylcarbonyl, and methylcarboxy, wherein each R4 is independently substituted by 0, 1, 2, or 3 R5.

### Claim 6 (depends on 1)

The compound of claim 1, wherein each R5 is independently selected from halogen, C1-6 alkyl, or C1-4 alkoxy,

### Claim 7 (depends on 1)

The compound of claim 1, wherein each R5 is independently selected from fluoro, C1-3 alkyl, or C1-4 alkoxy.

### Claim 8 (depends on 1)

The compound claim 1, wherein R3 is selected from methyl, ethyl, propyl, butyl, pentyl, difluoromethyl, trifluoromethyl, trifluoroethyl or hydrogen.

### Claim 9 (depends on 1)

The compound claim 1, wherein R3 is selected from methyl,
difluoromethyl, or hydrogen.

### Claim 10 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
5-[1-(cyclopropylmethyl)-2-oxo-1,8-diazaspiro[4.5]dec-8-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-{1-[(3-methyloxetan-3-yl)methyl]-2-oxo-3-oxa-1,8-diazaspiro[4.5]dec-8-yl}-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[1-(cyclopropylmethyl)-2-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-{1-(cyclopropylmethyl)-3-[2-(dimethylamino)ethyl]-2-oxo-1,3,8-triazaspiro[4.5]dec-8-yl}-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-{3-[2-(dimethylamino)ethyl]-2-oxo-1-(2,2,2-trifluoro-1-methylethyl)-1,3,8-triazaspiro[4.5]dec-8-yl}-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[1-(cyclopropylmethyl)-2,2-dioxido-2-thia-1,3,8-triazaspiro[4.5]dec-8-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[4-(cyclopropylmethyl)-2-oxo-3-oxa-1,8-diazaspiro[4.5]dec-8-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-(4-ethyl-3-oxo-2,8-diazaspiro[4.5]dec-8-yl)-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[1-(cyclopropylmethyl)-3-(2-methoxyethyl)-2-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[1-(2-methylpropyl)-3-oxo-2-oxa-4,9-diazaspiro[5.5]undec-9-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
3-(1-methyl-1H-pyrazol-4-yl)-5-[2-oxo-1-(2,2,2-trifluoroethyl)-1,3,8-triazaspiro[4.5]dec-8-yl]pyrazine-2-carbonitrile;
5-[1-(cyclopropylmethyl)-2-oxo-3-oxa-1,8-diazaspiro[4.5]dec-8-yl]-3-[1-(difluoromethyl)-1H-pyrazol-4-yl]pyrazine-2-carbonitrile;
3-[(3R)-4-(cyclopropylcarbonyl)-3-methylpiperazin-1-yl]-5-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[(3R)-3-methyl-4-{[(1R,2R)-2-methylcyclopropyl]carbonyl}piperazin-1-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[(3R)-4-(cyclopropylcarbonyl)-3-methylpiperazin-1-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
(2R)-4-[5-cyano-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl]-N-cyclopropyl-2-methylpiperazine-1-carboxamide;
3-[1-(difluoromethyl)-1H-pyrazol-4-yl]-5-[(3R)-3-methyl-4-{[(1R,2R)-2-methylcyclopropyl]carbonyl}piperazin-1-yl]pyrazine-2-carbonitrile;
5-[(3R)-4-(cyclopropylcarbonyl)-3-methylpiperazin-1-yl]-3-[1-(˜2˜H_3_)methyl-1H-pyrazol-4-yl]pyrazine-2-carbonitrile;
5-[(3R)-4-(cyclopropylcarbonyl)-3-(2-methylpropyl)piperazin-1-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-{1-[(3,3-difluorocyclobutyl)methyl]-2-oxo-1,8-diazaspiro[4.5]dec-8-yl}-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
3-(1-methyl-1H-pyrazol-4-yl)-5-[2-oxo-1-(2,2,2-trifluoroethyl)-1,8-diazaspiro[4.5]dec-8-yl]pyrazine-2-carbonitrile;
3-(1-methyl-1H-pyrazol-4-yl)-5-(2-oxo-1-propyl-3-oxa-1,8-diazaspiro[4.5]dec-8-yl)pyrazine-2-carbonitrile;
5-[1-(cyclobutylmethyl)-2-oxo-3-oxa-1,8-diazaspiro[4.5]dec-8-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[1-(cyclopropylmethyl)-2-oxo-4-oxa-1,9-diazaspiro[5.5]undec-9-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-(4-methyl-4-morpholin-4-ylpiperidin-1-yl)-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-(4′-methyl-1,4′-bipiperidin-1′-yl)-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-{(3R)-4-[(cis-3-methoxycyclobutyl)carbonyl]-3-methylpiperazin-1-yl}-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-{(3R)-4-[(3,3-difluorocyclobutyl)carbonyl]-3-methylpiperazin-1-yl}-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[(3R)-4-{[(1S,2S)-2-fluorocyclopropyl]carbonyl}-3-methylpiperazin-1-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[(3R)-3-methyl-4-propanoylpiperazin-1-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-{(3R)-3-methyl-4-[(1-methylcyclopropyl)carbonyl]piperazin-1-yl}-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
3-(1-methyl-1H-pyrazol-4-yl)-5-[(3R)-3-methyl-4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl]pyrazine-2-carbonitrile;
5-[(3R)-3-methyl-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)piperazin-1-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
(2R)-4-[5-cyano-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl]-N-(cyclopropylmethyl)-2-methylpiperazine-1-carboxamide;
5-[(3R)-4-{[(3S)-3-methoxypyrrolidin-1-yl]carbonyl}-3-methylpiperazin-1-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-{(3R)-4-[(3-methoxyazetidin-1-yl)carbonyl]-3-methylpiperazin-1-yl}-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
5-[(3R)-4-(azetidin-1-ylcarbonyl)-3-methylpiperazin-1-yl]-3-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carbonitrile;
methyl (2R)-4-[5-cyano-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl]-2-methylpiperazine-1-carboxylate; or
5-[(3R)-3-methyl-4-{[(R,2R)-2-methylcyclopropyl]carbonyl}piperazin-1-yl]-3-(1H-pyrazol-4-yl)pyrazine-2-carbonitrile.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, further comprising one or more other therapeutic agents.

### Claim 13 (depends on 1)

A method for the treatment of a PI3K-delta-mediated disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt or a stereoisomer thereof.

### Claim 14 (depends on 1)

A method of treating a condition in a mammal that can be ameliorated by the selective inhibition of PI3K-delta which condition is selected from: arthritis, asthma and obstructive airways diseases, autoimmune diseases or disorders, and cancer comprising administering to the mammal in need of such treatment, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt or a stereoisomer thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said condition is arthritis.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said condition is selected from rheumatoid arthritis, juvenile arthritis, and psoriatic arthritis.

### Claim 17 (depends on 14)

The method according to claim 14, wherein said condition is asthma or obstructive airways diseases.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said condition is selected from: chronic asthma, late asthma, airway hyper-responsiveness, bronchitis, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, recurrent airway obstruction, and chronic obstruction pulmonary disease (COPD), and emphysema.

### Claim 19 (depends on 1)

A method of treating asthma in a mammal in need thereof, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

A method of treating arthritis in a mammal in need thereof, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A method of treating cancer in a mammal in need thereof, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
